Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Nutritional Intervention to Prevent Metabolic Disease in Offspring Exposed to SSRI Antidepressants During the Perinatal Period
EF 2023-24
Résumé
Pregnancy is a window of vulnerability for depression with prevalence rates as high as 20% among pregnant people. Between 3 to 10% of people take antidepressants during pregnancy, with selective serotonin reuptake inhibitors (SSRIs), being the most prescribed. In humans, SSRI use during pregnancy has been associated with adverse metabolic outcomes such as increased adiposity, insulin resistance, dysglycemia and fatty liver in the offspring. Importantly, as metabolic dysfunction is believed to originate during fetal development, and oxidative stress is known to play an important role in the development of metabolic diseases in humans and animal models, an intervention with the antioxidant astaxanthin (ASX) during the perinatal period may prevent or reverse the metabolic impairments induced by SSRIs in the offspring. The goal of my project is to test the hypothesis that in a rat model, ASX administration during the perinatal period can prevent the development of adverse metabolic outcomes in SSRI-exposed offspring. I will determine if ASX treatment can prevent SSRI-induced dysmetabolism. I will assess offspring metabolic phenotypes (energy balance; lipid and glucose homeostasis) and the development of fatty liver (liver pathology, lipid content, and lipidomics) in SSRI-exposed and control animals. I will also examine the mechanisms by which ASX can prevent SSRI-induced dysmetabolism in offspring by measuring oxidative damage, antioxidant enzyme expression, and mitochondrial electron transport chain activity. This study aims to determine if a dietary intervention during pregnancy can reduce adverse metabolic outcomes in SSRI-exposed offspring, offering insights into the potential mechanism of action for ASX intervention and modulation of SSRI-associated risks.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506204
Name
Ruan Celina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Nutritional Intervention to Prevent Metabolic Disease in Offspring Exposed to SSRI Antidepressants During the Perinatal Period
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antidepressants; Astaxanthin; Early Life Influences On Offspring Health; Fluoxetine; Metabolic Dysfunction; Mitochondrial Dysfunction; Oxidative Stress; Perinatal Period; Pregnancy; Selective Serotonin Reuptake Inhibitors (Ssris)
Abstract
Pregnancy is a window of vulnerability for depression with prevalence rates as high as 20% among pregnant people. Between 3 to 10% of people take antidepressants during pregnancy, with selective serotonin reuptake inhibitors (SSRIs), being the most prescribed. In humans, SSRI use during pregnancy has been associated with adverse metabolic outcomes such as increased adiposity, insulin resistance, dysglycemia and fatty liver in the offspring. Importantly, as metabolic dysfunction is believed to originate during fetal development, and oxidative stress is known to play an important role in the development of metabolic diseases in humans and animal models, an intervention with the antioxidant astaxanthin (ASX) during the perinatal period may prevent or reverse the metabolic impairments induced by SSRIs in the offspring. The goal of my project is to test the hypothesis that in a rat model, ASX administration during the perinatal period can prevent the development of adverse metabolic outcomes in SSRI-exposed offspring. I will determine if ASX treatment can prevent SSRI-induced dysmetabolism. I will assess offspring metabolic phenotypes (energy balance; lipid and glucose homeostasis) and the development of fatty liver (liver pathology, lipid content, and lipidomics) in SSRI-exposed and control animals. I will also examine the mechanisms by which ASX can prevent SSRI-induced dysmetabolism in offspring by measuring oxidative damage, antioxidant enzyme expression, and mitochondrial electron transport chain activity. This study aims to determine if a dietary intervention during pregnancy can reduce adverse metabolic outcomes in SSRI-exposed offspring, offering insights into the potential mechanism of action for ASX intervention and modulation of SSRI-associated risks.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ruan, Celina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~